
The AIDS Crisis Offers a Warning About Trump's Research Cuts
I had AIDS. Everyone said it would kill me.
However, I did not die. Thanks to incredible medical research, AIDS was converted from certain death to possible life for those with access to new drugs. Today about 1.2 million Americans live with HIV/AIDS and 50,000 or so are added to this total each year. Thanks to drugs many people can't afford, an AIDs diagnosis is no longer a death sentence. Medicaid is redemptive. Federal resources save lives. And I am alive to bear witness to the danger that still lurks in our communities, to the enormous cost already paid in money and lives, and to the tremendous advancements we are making against this disease.
If we're willing to learn, our experience with AIDS offers some lessons. For example: Science, if persistently supported, can generate miracles. Science has kept me alive all these years. Science has virtually eradicated vertical (mother-to-child) HIV transmission for a few pennies per person. The miracles are within reach. But if scientific funding is stopped, so are the miracles.
The Trump Administration has gutted America's AIDS eradication program and HIV research initiatives. Republicans have simultaneously provided a historic tax cut for wealthy Americans. The unpleasant truth is that these policies are a reflection of a broader belief that some lives are more valuable than others.
As the philosophy goes: Infants in, say, Sudan can be allowed to die because their lives aren't as important as American's. And funding for the Supplemental Nutrition Assistance Program (SNAP), which feeds hungry families and school kids, can be cut because their lives don't matter as much as wealthy Americans need a tax break.
Burdening the poor with greater poverty while lightening the tax load of the most wealthy, to paraphrase Bill Gates, smacks of the richest people in the world killing the poorest children in the world.
The dilemma we faced with the AIDS crisis, and we face again today with President Donald Trump's reckless dismantling of domestic and international programs, is that those setting the rules believe they themselves will not be impacted.
What it will take to change minds, as we learned in the AIDS epidemic, is a personal encounter with the truth—and with the repercussions of their actions. When a Republican Congressman who voted for Trump's budget learns that his mother's rural nursing home has been closed, and there's no other one within a hundred miles, then he may care. When his eight-year-old daughter is given a terminal diagnosis, and his prayers for a miracle are not answered because research has been starved of needed funds, then he may care. When the consequences are close enough, personal enough, painful enough, we begin to care.
When we care enough about hunger, we can and will solve it—just like when we cared enough about AIDS, we were able to make huge strides. But right now, we simply do not care enough.
The AIDS epidemic taught us that until we are personally touched by the truth, we're not likely to care; and until we care, we'll stand by, hands in pockets, looking the other way. Cuts in USAID programs alone will result in the deaths of 14 million people, maybe more, who might have otherwise lived. But if their deaths are in another place, somewhere we won't be bothered by seeing them, we just don't care.
If we wait until we care enough, we'll learn the lesson of Pastor Niemoeller who said of Nazi Germany: 'They came after the Jews and I was not a Jew, so I did not protest. They came after the trade unionists and I was not a trade unionist, so I did not protest. They came after the Roman Catholics and I was not a Roman Catholic, so I did not protest. Then they came after me, and there was no one left to protest.' It's an old warning, one I cited in a speech to Republicans 33 years ago.
If we wait too long, and if we refuse to care about the lives of others, we will all eventually feel the consequences.
Then we will care.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
10 minutes ago
- San Francisco Chronicle
The Latest: Trump planning for Putin-Zelenskyy meeting while affirming security guarantees
President Donald Trump said he's begun arrangements for a face-to-face meeting between Vladimir Putin and Volodymyr Zelenskyy to discuss a pathway to end Russia's invasion of Ukraine. Trump affirmed that the U.S. would back European security guarantees but stopped short of committing U.S. troops to a collective effort to prevent Moscow from reinvading its neighbor. Relying on the false information and conspiracy theories that he's regularly used to explain away his 2020 election loss, Trump has pledged again to get rid of both mail voting, used by about one-third of all voters, and voting machines used in nearly all of the nation's election jurisdictions. Based on the Constitution, U.S. elections are managed by the states, and there is little to no way for Trump to change this. Trump says he didn't speak with Putin with European leaders in the room The president said he thought it would have been disrespectful to handle the phone call that way since Putin and the European leaders meeting with him at the White House haven't had the 'warmest relations.' But despite that, he said during an interview on Fox News Channel's 'Fox and Friends' that he has managed to maintain a 'very good relationship' with Putin. Trump was holding talks at the White House on Monday with Zelenskyy and the leaders of Britain, France, Germany, Italy, Finland, the European Union and NATO on ending Russia's war on Ukraine The president, in a morning interview on 'Fox & Friends,' said that he's optimistic a deal can be made to bring an end to Russia's invasion of Ukraine. But Trump underscored that Ukraine will have to set aside both its hope of a returned Crimea, which Russia seized by force in 2014, and its aspirations to join the NATO military alliance. 'Both of those things are impossible,' Trump said. Putin, as part of any potential deal, is looking for the withdrawal of Ukrainian troops from the Donetsk and Luhansk regions, as well as recognition of Crimea as Russian territory. Government argued 'Alligator Alcatraz' lawsuits need a different court The state and federal government had argued that even though the isolated airstrip where the facility is located is owned by Miami-Dade County, Florida's southern district was the wrong venue since the detention center is located in neighboring Collier County, which is in the state's middle district. The defendants made an identical argument last week about jurisdiction for a second lawsuit in which environmental groups and the Miccosukee Tribe sued to stop further construction and operations at the Everglades detention center until it's in compliance with federal environmental laws. U.S. District Judge Kathleen Williams in Miami has yet to rule on the venue question. On Aug. 7 she ordered a 14-day halt on additional construction during a hearing last week and said she plans to rule before the order expires this week. Judge dismisses part of lawsuit against 'Alligator Alcatraz' lawsuit A federal judge in Miami dismissed part of a lawsuit over the legal rights of detainees at the 'Alligator Alcatraz' immigration detention center and moved the case to a different jurisdiction. U.S. District Judge Rodolfo Ruiz's 47-page ruling late Monday says claims the detainees lack confidential access to their lawyers or to immigration hearings were rendered moot when the Trump administration recently designated the Krome North Processing Center near Miami as a site for their cases to be heard. The judge heard arguments from both sides in a hearing earlier Monday in Miami. Civil rights attorneys were seeking a preliminary injunction to ensure detainees at the facility have access to their lawyers and can get a hearing. Next steps in the negotiations turn back to Putin Trump, who bragged on numerous occasions during the campaign that he could settle Russia's war in Ukraine in a day, said repeatedly Monday that it was far more complicated than he ever thought it would be. But he also suggested — likely implausibly — that the fighting that has raged for years could wind down quickly. 'A week or two weeks, we'll know whether we're going to solve this, or if this horrible fighting is going to continue,' said Trump, even suggesting the issues yet to be hammered out weren't 'overly complex.' Still, much remains unresolved, including red lines that are incompatible — like whether Ukraine will cede any land to Russia, the future of Ukraine's army and whether the country will ultimately have lasting and meaningful security guarantees. Zelenskyy says meeting with Putin should be held 'without any conditions' Zelenskyy says that if he starts to set conditions for the meeting, regarding a potential ceasefire or other matters, then Russia will want to set conditions, too, potentially jeopardizing those talks. 'That's why I believe that we must meet without any conditions,' he told reporters. Zelenskyy said Trump showed him a map of the Ukraine front lines in the Oval Office and they got into a little debate about territories it showed. But they didn't argue, he said. 'We had a truly warm, good and substantial conversation,' Zelenskyy said. NATO leader says 'Article 5 kind of security guarantees' will be discussed in coming days NATO Secretary General Mark Rutte says Trump agreed that the United States would contribute to Ukraine's security following a peace deal, a development he called 'a breakthrough.' Membership in NATO is not on the table, but the U.S. and European leaders are discussing 'Article 5 kind of security guarantees for Ukraine,' Rutte said in an interview with Fox News host Laura Ingraham. Article 5 of the NATO treaty says an attack on one member nation is an attack on all members, the heart of the transatlantic defense compact. Details around U.S. involvement in Ukraine 'will be discussed over the coming days,' which will give Zelenskyy the clarity he needs to decide whether Ukrainians can remain safe following a peace deal. 'It is important to also know what the situation will be with the security guarantees to prevent Vladimir Putin from ever, ever trying again to invade parts of Ukraine,' Rutte said. The possibility of U.S. troops in Ukraine was not discussed Monday, he said. DC told of intent to arm National Guard troops Washington has been informed about the intent for the National Guard to be armed, though it has not received details about when that could happen or where armed Guard members could be deployed in D.C., according to a person familiar who was not authorized to disclose the plans and spoke on condition of anonymity. It would be a departure from what the Pentagon and Army have said about the troops being unarmed. The Army said in a statement last week that 'weapons are available if needed but will remain in the armory.' Pentagon press secretary Kingsley Wilson also said last week that troops won't be armed. In response to questions about whether Guard members in Washington would be armed in the coming days, the District of Columbia National Guard said troops 'may be armed consistent with their mission and training.' Maj. Melissa Heintz, a spokesperson for the D.C. Guard, didn't provide more details and said 'their presence is focused on supporting civil authorities and ensuring the safety of the community they serve.'


San Francisco Chronicle
10 minutes ago
- San Francisco Chronicle
Nexstar Media Group buying Tegna in deal worth $6.2 billion
Nexstar Media Group is buying broadcast rival Tegna for $6.2 billion, which will help strengthen its local news offerings. The transaction, if approved, will bring together two major players in U.S. television and the country's local news landscape. Nexstar oversees more than 200 owned and partner stations in 116 markets nationwide today and also runs networks like The CW and NewsNation. Meanwhile, Tegna owns 64 news stations across 51 markets. 'The initiatives being pursued by the Trump administration offer local broadcasters the opportunity to expand reach, level the playing field, and compete more effectively with the Big Tech and legacy Big Media companies that have unchecked reach and vast financial resources," Nexstar Chairman and CEO Perry Sook said in a statement on Tuesday. 'We believe Tegna represents the best option for Nexstar to act on this opportunity.' Nexstar said Tuesday that the deal will also help it give advertisers a bigger variety of local and national broadcast and digital advertising options. Nexstar will pay $22 in cash for each share of Tegna's outstanding stock. The deal could potentially help kick off even further consolidation in America's broadcast industry. Nexstar, founded in 1996, has itself grow substantially with acquisitions over the latest two decades, becoming the biggest operator of local TV stations in the U.S. after it purchased Tribune Media back in 2019. Nexstar's purchase of Tegna also arrives amid wider regulatory shifts. Brendan Carr, the Trump-appointed chairman the Federal Communications Commission, which will need to give the transaction the green light, has long advocated for loosening industry restrictions. On Aug. 7, the FCC announced that it would be repealing 98 broadcast rules and requirements that it identified as 'obsolete, outdated, or unnecessary.' Some of those rules date back nearly 50 years, the FCC said, and apply to 'old technology that is no longer used." Carr maintained that such provisions no longer serve public interest. In late July, the U.S. Court of Appeals for the Eighth Circuit also vacated the FCC's 'top four' rule, which has long prohibited ownership of more than one of the top four stations in a single market. The ruling is still subject to a monthslong assessment by the FCC, but could significantly clear the way for future mergers in the industry. In company earnings calls held in early August, before Tegna and Nexstar publicly confirmed merger talks, both Tegna CEO Michael Steib and Nexstar's Sook pointed directly to this ruling, and applauded Carr's deregulation agenda as a whole. 'We believe that deregulation is necessary, important and coming,' Steib said in Tegna's Aug. 7 call, noting that local broadcasters are 'up against big tech competitors who have absolutely no encumbrances in how they compete." Beyond their core broadcast TV businesses, both Nexstar and Tegna also boast digital news, mobile app and streaming offerings, all of which have played key roles for the industry as consumers change the way they consume news and other entertainment. Broadcast TV has been hit particularly hard by 'cord-cutting,' with more and more households trading their cable or satellite subscriptions into content they can get via the internet.


Business Wire
10 minutes ago
- Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA ® in Patients with Long COVID
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a significant public health challenge with no currently available established therapies. The new study, called COVID-4.019-Long, further expands the company's clinical research efforts to assess ANKTIVA's potential beyond cancer or cancer-related diseases. Currently, ANKTIVA is being evaluated alone and with other agents in multiple studies for different forms of bladder cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin lymphoma, Lynch syndrome, ovarian cancer and Human Papillomavirus (HPV) associated tumors. ANKTIVA is also being studied in Human Immunodeficiency Virus (HIV) and lymphopenia. The primary objective of the exploratory, single-arm study (NCT0712372 7) is to evaluate the safety of ANKTIVA, injected under the skin (subcutaneously), in participants with long COVID. The secondary objective is to assess the effect of ANKTIVA on absolute lymphocyte count. Exploratory objectives include evaluation of ANKTIVA's ability to improve post-COVID natural killer (NK) cell and CD8+ T cell counts, and assessment of the immunological function of NK cells and CD8+ T cells. 'We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,' said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. 'Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.' The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit ANKTIVA is currently approved by the U.S. Food and Drug Administration with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. About Long COVID Long COVID is a serious illness that can cause chronic health conditions requiring comprehensive care. It may also lead to disability. 2 Long COVID impacts approximately 1 in 5 Americans adults who had a previous COVID-19 infection. 1 It can include a wide range of ongoing symptoms and conditions that can last weeks, months, or even years after COVID-19 illness. 1 Some of the common among the more than 200 identified symptoms include fatigue, brain fog, coughing, shortness of breath, heart palpitations and change in smell or taste. 3 Anyone who had a SARS-CoV-2 infection, the virus that causes COVID-19, can experience Long COVID, including children. 1 Long COVID remains a significant public health challenge with no currently available established treatments. About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. A key component in the company's BioShield platform, ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Prescribing Information for ANKTIVA ® at References: Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis. May 3 2023;76(9):1636-1645. U.S. Centers for Disease Control and Prevention. Long COVID Basics. July 2025. Available at U.S. Centers for Disease Control and Prevention. Long COVID Signs and Symptoms. July 2025. Available at About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the potential health conditions associated with Long COVID, potential patient populations and implications thereof, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'goal,' 'could,' 'estimates,' 'scheduled,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'predicts,' 'indicate,' 'projects,' 'is,' 'seeks,' 'should,' 'will,' 'strategy,' and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading 'Risk Factors' in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.